{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:08:53Z","timestamp":1791220133676,"version":"4.1.0"},"reference-count":51,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100005032","name":"Funda\u00e7\u00e3o Bial","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pain is a common non\u2010motor symptom in Parkinson\u2019s disease (PD) and is often associated to fluctuations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation\u2010related pain when added to levodopa therapy in PD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with PD with end\u2010of\u2010dose motor fluctuations and associated pain were randomized to opicapone 50\u2009mg or placebo for 24\u2009weeks. The primary end point was reduction from baseline to week 24 in the King's Parkinson's Disease Pain Scale (KPPS) domain 3. Reductions in KPPS and Movement Disorder Society\u2013sponsored Non\u2010Motor Rating Scale (MDS\u2010NMS) total scores and safety\/tolerability were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 122 patients were included (opicapone, n\u2009=\u200959; placebo, n\u2009=\u200963). Mean (standard deviation) change from baseline in KPPS domain 3 was \u22128.8 (6.9) points in the opicapone group versus \u22129.3 (6.2) points in the placebo group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.7940). Opicapone resulted in numerically greater reductions versus placebo in KPPS and MDS\u2010NMS total scores and was generally well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Opicapone did not reach statistical superiority over placebo, highlighting the complexities of studying pain in PD. \u00a9 2026 The Author(s).\n                      <jats:italic>Movement Disorders<\/jats:italic>\n                      published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mds.70390","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:51:08Z","timestamp":1780969868000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Challenges of Pain in Parkinson's Disease: Results from the\n                    <scp>OCEAN<\/scp>\n                    Study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-0505","authenticated-orcid":false,"given":"Kallol Ray","family":"Chaudhuri","sequence":"first","affiliation":[{"name":"Parkinson's Centre of Excellence King's College Hospital London  Dubai United Arab Emirates"},{"name":"Dementech Neurosciences Clinical Academic Centre  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina Universidade de Lisboa  Lisbon Portugal"},{"name":"CNS \u2013 Campus Neurol\u00f3gico  Torres Vedras Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-2807","authenticated-orcid":false,"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[{"name":"Neurodegenerative Disease Unit, Department of Neurosciences, PNC University of Padova  Padova Italy"},{"name":"IRCCS San Camillo  Venice Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[{"name":"Toulouse Parkinson Expert Center, Department of Neurosciences and Clinical Pharmacology, Centre d'Investigation Clinique de Toulouse CIC1436, NS\u2010Park\/FCRIN Network, and NeuroToul COEN Center, University Hospital of Toulouse, INSERM University of Toulouse 3  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M.","family":"Kurtis","sequence":"additional","affiliation":[{"name":"Movement Disorders Unit, Neurology Department Hospital Ruber Internacional  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1133-9216","authenticated-orcid":false,"given":"Alexander","family":"Storch","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Center Rostock University of Rostock, and DZNE Research site Rostock\u2010Greifswald  Rostock Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9\u2010Francisco","family":"Rocha","sequence":"additional","affiliation":[{"name":"BIAL \u2013 Portela &amp; Ca S.A.  Coronado Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Costa","sequence":"additional","affiliation":[{"name":"BIAL \u2013 Portela &amp; Ca S.A.  Coronado Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"BIAL \u2013 Portela &amp; Ca S.A.  Coronado Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Castilla\u2010Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"BIAL \u2013 Portela &amp; Ca S.A.  Coronado Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena C.","family":"Brigas","sequence":"additional","affiliation":[{"name":"BIAL \u2013 Portela &amp; Ca S.A.  Coronado Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Holenz","sequence":"additional","affiliation":[{"name":"BIAL \u2013 Portela &amp; Ca S.A.  Coronado Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Clinical Sciences Lund Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the OCEAN study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"7","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"917\u2010e969","DOI":"10.1111\/ene.13624","article-title":"Pain in Parkinson's disease: facts and uncertainties","volume":"25","author":"Antonini A","year":"2018","journal-title":"Eur J Neurol"},{"issue":"11","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","article-title":"The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease","volume":"24","author":"Barone P","year":"2009","journal-title":"Mov Disord"},{"key":"e_1_2_10_4_1","first-page":"1","article-title":"An overview of pain in Parkinson's disease","volume":"2","author":"Tai YC","year":"2020","journal-title":"Clin Park Relat Disord"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107123","article-title":"Recognition and characterising non\u2010motor profile in early onset Parkinson's disease (EOPD)","volume":"129","author":"Poplawska\u2010Domaszewicz K","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.3233\/JPD-202069","article-title":"Management of Pain in Parkinson's disease","volume":"10","author":"Buhmann C","year":"2020","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s00415-017-8426-y","article-title":"Pain in Parkinson disease: a cross\u2010sectional survey of its prevalence, specifics, and therapy","volume":"264","author":"Buhmann C","year":"2017","journal-title":"J Neurol"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.parkreldis.2020.09.024","article-title":"Unmet needs in Parkinson disease: motor and non\u2010motor","volume":"80","author":"LeWitt PA","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0b013e318285c0ed","article-title":"Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications","volume":"80","author":"Storch A","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejphar.2004.07.024","article-title":"Striatal dopamine D2 receptors in modulation of pain in humans: a review","volume":"500","author":"Hagelberg N","year":"2004","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease\u2010an evidence\u2010based medicine review","volume":"34","author":"Seppi K","year":"2019","journal-title":"Mov Disord"},{"issue":"12","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1474-4422(15)00243-4","article-title":"Prolonged\u2010release oxycodone\u2010naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double\u2010blind, randomised, placebo\u2010controlled trial","volume":"14","author":"Trenkwalder C","year":"2015","journal-title":"Lancet Neurol"},{"issue":"7","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/jcph.678","article-title":"A randomized controlled exploratory pilot study to evaluate the effect of Rotigotine transdermal patch on Parkinson's disease\u2010associated chronic pain","volume":"56","author":"Rascol O","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_10_14_1","unstructured":"ClinicalTrials.gov. Effect of Safinamide on Parkinson's Disease Related Chronic Pain;2019."},{"issue":"9","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/mds.29878","article-title":"Oxycodone or higher dose of levodopa for the treatment of parkinsonian central pain: OXYDOPA trial","volume":"39","author":"Brefel\u2010Courbon C","year":"2024","journal-title":"Mov Disord"},{"issue":"10","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/ene.12757","article-title":"Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non\u2010motor symptoms \u2010 results of a double\u2010blind, randomized, placebo\u2010controlled trial","volume":"22","author":"Antonini A","year":"2015","journal-title":"Eur J Neurol"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116833","article-title":"A double\u2010blind, randomized controlled trial of duloxetine for pain in Parkinson's disease","volume":"414","author":"Iwaki H","year":"2020","journal-title":"J Neurol Sci"},{"issue":"2","key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","article-title":"Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end\u2010of\u2010dose motor fluctuations: a randomised, double\u2010blind, controlled trial","volume":"15","author":"Ferreira JJ","year":"2016","journal-title":"Lancet Neurol"},{"issue":"2","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","article-title":"Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Lees AJ","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-020-00187-1","article-title":"Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open\u2010label study","volume":"9","author":"Reichmann H","year":"2020","journal-title":"Transl Neurodegener"},{"issue":"3","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12030383","article-title":"Opicapone improves global non\u2010motor symptoms burden in Parkinson's disease: an open\u2010label prospective study","volume":"12","author":"Santos Garc\u00eda D","year":"2022","journal-title":"Brain Sci"},{"key":"e_1_2_10_22_1","first-page":"S15","article-title":"Spontaneous and evoked pain in parkinson's disease with motor fluct uat ions: an observational, prospective, clinical and neurophysiological study in patients under l\u2010dopa and opicapone add on therapy","volume":"44","author":"Geroin CTM","year":"2023","journal-title":"Neurol Sci"},{"issue":"1","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00702-023-02700-y","article-title":"A 12\u2010month prospective real\u2010life study of opicapone efficacy and tolerability in Emirati and non\u2010white subjects with Parkinson's disease based in United Arab Emirates","volume":"131","author":"Metta V","year":"2024","journal-title":"J Neural Transm (Vienna)"},{"issue":"12","key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/mds.26270","article-title":"King's Parkinson's disease pain scale, the first scale for pain in PD: an international validation","volume":"30","author":"Chaudhuri KR","year":"2015","journal-title":"Mov Disord"},{"issue":"1","key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12883-022-02602-8","article-title":"Opicapone versus placebo in the treatment of Parkinson's disease patients with end\u2010of\u2010dose motor fluctuation\u2010associated pain: rationale and design of the randomised, double\u2010blind OCEAN (OpiCapone effect on motor fluctuations and pAiN) trial","volume":"22","author":"Chaudhuri KR","year":"2022","journal-title":"BMC Neurol"},{"issue":"10","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1080\/09638288.2022.2074152","article-title":"Minimal clinically important difference of the King's Parkinson's disease pain scale","volume":"45","author":"Taghizadeh G","year":"2023","journal-title":"Disabil Rehabil"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clinph.2024.01.011","article-title":"TDCS for parkinson's disease disease\u2010related pain: a randomized trial","volume":"161","author":"Gonz\u00e1lez\u2010Zamorano Y","year":"2024","journal-title":"Clin Neurophysiol"},{"issue":"8","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/ene.12724","article-title":"A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non\u2010demented Parkinson's disease patients","volume":"22","author":"Barone P","year":"2015","journal-title":"Eur J Neurol"},{"issue":"5","key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/mds.21894","article-title":"Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions","volume":"23","author":"Goetz CG","year":"2008","journal-title":"Mov Disord"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106503","article-title":"What can be done to control the placebo response in clinical trials? A narrative review","volume":"107","author":"Evans K","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/j.bja.2019.01.040","article-title":"Pain, placebo, and test of treatment efficacy: a narrative review","volume":"123","author":"Vase L","year":"2019","journal-title":"Br J Anaesth"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.irn.2020.03.031","article-title":"Placebo responses in Parkinson's disease","volume":"153","author":"Lou JS","year":"2020","journal-title":"Int Rev Neurobiol"},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-662-44519-8_8","article-title":"Great expectations: the placebo effect in Parkinson's disease","volume":"225","author":"Lidstone SC","year":"2014","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/npp.2010.81","article-title":"How placebos change the patient's brain","volume":"36","author":"Benedetti F","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"5532","key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1126\/science.1060937","article-title":"Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease","volume":"293","author":"Fuente\u2010Fern\u00e1ndez R","year":"2001","journal-title":"Science"},{"issue":"8","key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/mds.27438","article-title":"Neurobiology of placebo effect in Parkinson's disease: what we have learned and where we are going","volume":"33","author":"Quattrone A","year":"2018","journal-title":"Mov Disord"},{"issue":"5","key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.molmed.2015.02.009","article-title":"Genetics and the placebo effect: the placebome","volume":"21","author":"Hall KT","year":"2015","journal-title":"Trends Mol Med"},{"issue":"9","key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1111\/bcp.14766","article-title":"Improved estimates of mean pharmacokinetic parameters for increased accuracy in dosing and reduced risk to patients","volume":"87","author":"Scutt G","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"e_1_2_10_39_1","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14090939","article-title":"Addressing the ethnicity gap in catechol O\u2010methyl transferase inhibitor trials in Parkinson's disease: a review of available global data","volume":"14","author":"Poplawska\u2010Domaszewicz K","year":"2024","journal-title":"J Pers Med"},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1216975","article-title":"Effects of levodopa\u2010carbidopa intestinal gel compared with optimized medical treatment on nonmotor symptoms in advanced Parkinson's disease: INSIGHTS study","volume":"2022","author":"Chung SJ","year":"2022","journal-title":"Parkinsons Dis"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.parkreldis.2022.07.006","article-title":"Heterogeneous pain trajectories in persons with Parkinson's disease","volume":"102","author":"Gunzler DD","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"e_1_2_10_42_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1474-4422(22)00085-0","article-title":"Safety and efficacy of subcutaneous night\u2010time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double\u2010blind crossover study","volume":"21","author":"De Cock VC","year":"2022","journal-title":"Lancet Neurol"},{"issue":"3","key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/AJP.0000000000000670","article-title":"The multimodal assessment model of pain: a novel framework for further integrating the subjective pain experience within research and practice","volume":"35","author":"Wideman TH","year":"2019","journal-title":"Clin J Pain"},{"issue":"1","key":"e_1_2_10_44_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13643-019-1115-4","article-title":"Memory of pain in adults: a protocol for systematic review and meta\u2010analysis","volume":"8","author":"Adamczyk WM","year":"2019","journal-title":"Syst Rev"},{"issue":"1","key":"e_1_2_10_45_1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pain.2008.03.024","article-title":"The accuracy of pain and fatigue items across different reporting periods","volume":"139","author":"Broderick JE","year":"2008","journal-title":"Pain"},{"issue":"2","key":"e_1_2_10_46_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpain.2003.11.005","article-title":"Memory for stress\u2010associated acute pain","volume":"5","author":"Gedney JJ","year":"2004","journal-title":"J Pain"},{"issue":"1","key":"e_1_2_10_47_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pain.2005.12.005","article-title":"Pain related recall predicts future pain report","volume":"121","author":"Gedney JJ","year":"2006","journal-title":"Pain"},{"issue":"1","key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1877718X241306711","article-title":"Opicapone for Parkinson's disease\u2010related sleep disturbances: the OASIS clinical trial","volume":"15","author":"Ferreira JJ","year":"2025","journal-title":"J Parkinsons Dis"},{"issue":"6","key":"e_1_2_10_49_1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/mdc3.14030","article-title":"Opicapone to treat early wearing\u2010off in Parkinson's disease patients: the Korean ADOPTION trial","volume":"11","author":"Lee JY","year":"2024","journal-title":"Mov Disord Clin Pract"},{"key":"e_1_2_10_50_1","unstructured":"FDA.Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products. Guidance for Industry;2019."},{"issue":"1","key":"e_1_2_10_51_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41531-023-00581-2","article-title":"Identification of motor progression in Parkinson's disease using wearable sensors and machine learning","volume":"9","author":"Sotirakis C","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"issue":"12","key":"e_1_2_10_52_1","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1345\/aph.1D172","article-title":"Meta\u2010analysis of placebo rates in major depressive disorder trials","volume":"37","author":"Stolk P","year":"2003","journal-title":"Ann Pharmacother"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.70390","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.70390","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.70390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:51:15Z","timestamp":1780969875000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.70390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":51,"alternative-id":["10.1002\/mds.70390"],"URL":"https:\/\/doi.org\/10.1002\/mds.70390","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"2025-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"mds.70390"}}